S&P 500   3,901.82
DOW   31,535.51
QQQ   323.59
S&P 500   3,901.82
DOW   31,535.51
QQQ   323.59
S&P 500   3,901.82
DOW   31,535.51
QQQ   323.59
S&P 500   3,901.82
DOW   31,535.51
QQQ   323.59
Log in
NYSE:BMY

Bristol-Myers Squibb Stock Forecast, Price & News

$61.63
+0.30 (+0.49 %)
(As of 03/1/2021 12:00 AM ET)
Add
Compare
Today's Range
$61.52
Now: $61.63
$62.07
50-Day Range
$59.40
MA: $62.51
$66.74
52-Week Range
$45.76
Now: $61.63
$67.16
Volume7.30 million shs
Average Volume13.04 million shs
Market Capitalization$138.08 billion
P/E RatioN/A
Dividend Yield3.20%
Beta0.67
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products in hematology, oncology, cardiovascular, and immunology therapeutic classes. The company's products include Opdivo for anti-cancer indications; Eliquis, an oral inhibitor targeted at stroke prevention in adult patients with non-valvular atrial fibrillation, and the prevention and treatment of venous thromboembolic disorders; and Orencia for adult patients with active RA and prostate-specific antigen, as well as reducing signs and symptoms in pediatric patients with active polyarticular juvenile idiopathic arthritis. It also provides Sprycel, a tyrosine kinase inhibitor for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy, a monoclonal antibody for the treatment of patients with unresectable or metastatic melanoma; Empliciti, a humanized monoclonal antibody for the treatment of multiple myeloma; and Baraclude, an oral antiviral agent for the treatment of chronic hepatitis B. In addition, it offers Reyataz, a protease inhibitor to treat human immunodeficiency virus (HIV); Sustiva franchise, a non-nucleoside reverse transcriptase inhibitor for the treatment of HIV; and Daklinza NS5A replication complex inhibitor, Sunvepra NS3 protease inhibitor, and Beclabuvir NS5B inhibitor. It sells products to wholesalers, retail pharmacies, hospitals, government entities, and medical profession. The company has collaboration agreements with Pfizer, Otsuka, Ono, Nektar, GRYT Health, Ubiquigent Limited, Checkmate Pharmaceuticals, and Sensyne Health plc; clinical collaboration with NeoImmuneTech, Inc.; partnership with Astrazeneca Plc; a discovery collaboration with Insitro, Inc.; and collaboration with Schrödinger, Inc. The company was formerly known as Bristol-Myers Company and changed its name to Bristol-Myers Squibb Company in 1989. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in New York, New York.
Bristol-Myers Squibb logo

Headlines

See More Headlines

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
CUSIP11012210
Phone212-546-4000
Employees30,000
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$26.15 billion
Cash Flow$4.07 per share
Book Value$23.20 per share

Profitability

Net Income$3.44 billion

Miscellaneous

Outstanding Shares2,240,475,000
Market Cap$138.08 billion
Next Earnings Date5/6/2021 (Estimated)
OptionableOptionable

MarketRank

Overall MarketRank

2.34 out of 5 stars

Medical Sector

21st out of 1,966 stocks

Pharmaceutical Preparations Industry

10th out of 772 stocks

Analyst Opinion: 2.4Community Rank: 2.6Dividend Strength: 2.5Insider Behavior: 1.7Valuation: 2.5 5 -4 -3 -2 -1 -
$61.63
+0.30 (+0.49 %)
(As of 03/1/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive BMY News and Ratings via Email

Sign-up to receive the latest news and ratings for BMY and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Bristol-Myers Squibb (NYSE:BMY) Frequently Asked Questions

Is Bristol-Myers Squibb a buy right now?

14 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Bristol-Myers Squibb in the last twelve months. There are currently 3 hold ratings, 10 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" Bristol-Myers Squibb stock.
View analyst ratings for Bristol-Myers Squibb
or view top-rated stocks.

What stocks does MarketBeat like better than Bristol-Myers Squibb?

Wall Street analysts have given Bristol-Myers Squibb a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Bristol-Myers Squibb wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Bristol-Myers Squibb?

Bristol-Myers Squibb saw a increase in short interest in January. As of January 15th, there was short interest totaling 19,730,000 shares, an increase of 31.4% from the December 31st total of 15,020,000 shares. Based on an average trading volume of 10,760,000 shares, the short-interest ratio is currently 1.8 days.
View Bristol-Myers Squibb's Short Interest
.

When is Bristol-Myers Squibb's next earnings date?

Bristol-Myers Squibb is scheduled to release its next quarterly earnings announcement on Thursday, May 6th 2021.
View our earnings forecast for Bristol-Myers Squibb
.

How were Bristol-Myers Squibb's earnings last quarter?

Bristol-Myers Squibb (NYSE:BMY) announced its quarterly earnings data on Wednesday, February, 3rd. The biopharmaceutical company reported $1.46 earnings per share for the quarter, beating the consensus estimate of $1.42 by $0.04. The biopharmaceutical company had revenue of $11.07 billion for the quarter, compared to analysts' expectations of $10.74 billion. Bristol-Myers Squibb had a negative net margin of 0.11% and a positive trailing twelve-month return on equity of 27.48%. Bristol-Myers Squibb's revenue was up 39.3% on a year-over-year basis. During the same period in the previous year, the business earned $1.22 earnings per share.
View Bristol-Myers Squibb's earnings history
.

How has Bristol-Myers Squibb's stock been impacted by COVID-19?

Bristol-Myers Squibb's stock was trading at $108.24 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, BMY stock has decreased by 43.1% and is now trading at $61.63.
View which stocks have been most impacted by COVID-19
.

How often does Bristol-Myers Squibb pay dividends? What is the dividend yield for Bristol-Myers Squibb?

Bristol-Myers Squibb announced a quarterly dividend on Thursday, December 10th. Shareholders of record on Monday, January 4th will be paid a dividend of $0.49 per share on Monday, February 1st. This represents a $1.96 annualized dividend and a yield of 3.18%. The ex-dividend date is Thursday, December 31st. This is a positive change from Bristol-Myers Squibb's previous quarterly dividend of $0.45.
View Bristol-Myers Squibb's dividend history
.

Is Bristol-Myers Squibb a good dividend stock?

Bristol-Myers Squibb pays an annual dividend of $1.96 per share and currently has a dividend yield of 3.20%. Bristol-Myers Squibb does not yet have a strock track record of dividend growth. The dividend payout ratio of Bristol-Myers Squibb is 41.79%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, Bristol-Myers Squibb will have a dividend payout ratio of 26.78% next year. This indicates that Bristol-Myers Squibb will be able to sustain or increase its dividend.
View Bristol-Myers Squibb's dividend history.

When did Bristol-Myers Squibb's stock split? How did Bristol-Myers Squibb's stock split work?

Bristol-Myers Squibb shares split on the morning of Thursday, June 26th 2014. The 2-1 split was announced on Thursday, June 19th 2014. The newly created shares were payable to shareholders after the market closes on Wednesday, June 25th 2014. An investor that had 100 shares of Bristol-Myers Squibb stock prior to the split would have 200 shares after the split.

What guidance has Bristol-Myers Squibb issued on next quarter's earnings?

Bristol-Myers Squibb updated its FY 2021 Pre-Market earnings guidance on Thursday, February, 4th. The company provided earnings per share guidance of 7.35-7.55 for the period, compared to the Thomson Reuters consensus estimate of $7.45.

What price target have analysts set for BMY?

14 Wall Street analysts have issued twelve-month price targets for Bristol-Myers Squibb's shares. Their forecasts range from $65.00 to $88.00. On average, they anticipate Bristol-Myers Squibb's share price to reach $74.64 in the next twelve months. This suggests a possible upside of 21.1% from the stock's current price.
View analysts' price targets for Bristol-Myers Squibb
or view top-rated stocks among Wall Street analysts.

Who are Bristol-Myers Squibb's key executives?

Bristol-Myers Squibb's management team includes the following people:
  • Dr. Giovanni Caforio, Chairman & CEO (Age 56, Pay $6.22M)
  • Mr. David V. Elkins, Exec. VP & CFO (Age 53, Pay $3.62M)
  • Ms. Sandra Leung Esq., Exec. VP & Gen. Counsel (Age 60, Pay $2.92M)
  • Dr. Christopher S. Boerner, Exec. VP & Chief Commercialization Officer (Age 50, Pay $2.49M)
  • Mr. Rupert Vessey M.A., Exec. VP and Pres of Research & Early Devel. (Age 56, Pay $3.31M)
  • Mr. Paul von Autenried, Exec. VP & Chief Information Officer (Age 59)
  • Mr. Timothy Power, VP & Head of Investor Relations
  • Mr. Adam Dubow, Sr. VP, Chief Compliance & Ethics Officer (Age 54)
  • Ms. Ann M. Powell Judge, Exec. VP & Chief HR Officer (Age 55)
  • Mr. Louis S. Schmukler, Exec. VP and Pres of Global Product Devel. & Supply (Age 65)

What is Giovanni Caforio's approval rating as Bristol-Myers Squibb's CEO?

659 employees have rated Bristol-Myers Squibb CEO Giovanni Caforio on Glassdoor.com. Giovanni Caforio has an approval rating of 89% among Bristol-Myers Squibb's employees.

Who are some of Bristol-Myers Squibb's key competitors?

What other stocks do shareholders of Bristol-Myers Squibb own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Bristol-Myers Squibb investors own include AbbVie (ABBV), AT&T (T), Pfizer (PFE), Johnson & Johnson (JNJ), Verizon Communications (VZ), Intel (INTC), NVIDIA (NVDA), CVS Health (CVS), Cisco Systems (CSCO) and Bank of America (BAC).

What is Bristol-Myers Squibb's stock symbol?

Bristol-Myers Squibb trades on the New York Stock Exchange (NYSE) under the ticker symbol "BMY."

Who are Bristol-Myers Squibb's major shareholders?

Bristol-Myers Squibb's stock is owned by many different retail and institutional investors. Top institutional shareholders include Dodge & Cox (1.18%), Primecap Management Co. CA (0.86%), Renaissance Technologies LLC (0.82%), Nordea Investment Management AB (0.58%), Charles Schwab Investment Management Inc. (0.47%) and Swiss National Bank (0.38%). Company insiders that own Bristol-Myers Squibb stock include Adam Dubow, Autenried Paul Von, Dinesh C Paliwal, Giovanni Caforio, John E Elicker, Joseph Eid, Karen Murphy Santiago, Louis S Schmukler, Robert J Bertolini, Rupert Vessey, Sandra Leung, Terrie Curran and Theodore R Samuels II.
View institutional ownership trends for Bristol-Myers Squibb
.

Which institutional investors are selling Bristol-Myers Squibb stock?

BMY stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Quinn Opportunity Partners LLC, State of Wisconsin Investment Board, FIL Ltd, Sumitomo Mitsui Trust Holdings Inc., Gabelli Funds LLC, Clearbridge Investments LLC, and PGGM Investments. Company insiders that have sold Bristol-Myers Squibb company stock in the last year include Adam Dubow, Autenried Paul Von, Giovanni Caforio, John E Elicker, Joseph Eid, Louis S Schmukler, Rupert Vessey, and Sandra Leung.
View insider buying and selling activity for Bristol-Myers Squibb
or view top insider-selling stocks.

Which institutional investors are buying Bristol-Myers Squibb stock?

BMY stock was bought by a variety of institutional investors in the last quarter, including State of Michigan Retirement System, Principal Financial Group Inc., State of Tennessee Treasury Department, Rothschild & Co. Asset Management US Inc., Factory Mutual Insurance Co., Toronto Dominion Bank, PFM Health Sciences LP, and AMF Pensionsforsakring AB. Company insiders that have bought Bristol-Myers Squibb stock in the last two years include Dinesh C Paliwal, Robert J Bertolini, and Theodore R Samuels II.
View insider buying and selling activity for Bristol-Myers Squibb
or or view top insider-buying stocks.

How do I buy shares of Bristol-Myers Squibb?

Shares of BMY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Bristol-Myers Squibb's stock price today?

One share of BMY stock can currently be purchased for approximately $61.63.

How much money does Bristol-Myers Squibb make?

Bristol-Myers Squibb has a market capitalization of $138.08 billion and generates $26.15 billion in revenue each year. The biopharmaceutical company earns $3.44 billion in net income (profit) each year or $4.69 on an earnings per share basis.

How many employees does Bristol-Myers Squibb have?

Bristol-Myers Squibb employs 30,000 workers across the globe.

What is Bristol-Myers Squibb's official website?

The official website for Bristol-Myers Squibb is www.bms.com.

Where are Bristol-Myers Squibb's headquarters?

Bristol-Myers Squibb is headquartered at 430 E. 29TH STREET 14 FLOOR, NEW YORK NY, 10016.

How can I contact Bristol-Myers Squibb?

Bristol-Myers Squibb's mailing address is 430 E. 29TH STREET 14 FLOOR, NEW YORK NY, 10016. The biopharmaceutical company can be reached via phone at 212-546-4000 or via email at [email protected]


This page was last updated on 3/2/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.